A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

A next-generation tumor-targeting IL-2 preferentially promotes tumor-infiltrating CD8+ T-cell response and effective tumor control

Interleukin-2 (IL-2) based cancer therapy is limited by severe toxicity and strong Treg amplification at the therapeutic dosage. Here, the authors develop a recombinant IL-2 immunocytokine which is comprised of a tumor-targeting antibody fused to a super mutant IL-2 and show in mouse models that thi...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Zhichen Sun, Zhenhua Ren, Kaiting Yang, Zhida Liu, Shuaishuai Cao, Sisi Deng, Lily Xu, Yong Liang, Jingya Guo, Yingjie Bian, Hairong Xu, Jiyun Shi, Fan Wang, Yang-Xin Fu, Hua Peng
Formato: article
Lenguaje:EN
Publicado: Nature Portfolio 2019
Materias:
Science
Q
Acceso en línea:https://doaj.org/article/d9466bada18644f1bed8cb45aa2a8e1a
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Internet

https://doaj.org/article/d9466bada18644f1bed8cb45aa2a8e1a

Ejemplares similares